Literature DB >> 8018955

Finite proliferative lifespan in vitro of a human breast cancer cell strain isolated from a metastatic lymph node.

M L Mahacek1, D G Beer, T S Frank, S P Ethier.   

Abstract

We recently described culture conditions that allow proliferation of metastatic human breast cancer cells from biopsy specimens of certain patient samples. These conditions resulted in the development of an immortalized cell strain designated SUM-44PE. These same culture conditions were used to isolate a human breast cancer cell strain from a metastatic lymph node of a separate breast cancer patient. The SUM-16LN human breast cancer cells isolated from this specimen were cultured either in serum-free medium or serum-containing medium supplemented with insulin and hydrocortisone. Unlike the SUM-44PE cells that have proliferated in culture continuously for over two years, SUM-16LN cells proliferated in culture for approximately 200 days and underwent 15 to 20 population doublings before undergoing cell senescence. No cells of this strain proliferated beyond passage 8. SUM-16LN cells were keratin-19 positive and had an aneuploid karyotype. These cells overexpressed p53 protein and had an amplified epidermal growth factor (EGF) receptor gene that resulted in high level expression of tyrosine phosphorylated EGF receptor protein. Despite the presence of high levels of tyrosine phosphorylated EGF receptor in these cells, they proliferated in serum-free, EGF-free medium and did not secrete detectable levels of EGF-like mitogenic growth factor. In addition, these cells were potently growth inhibited by all concentrations of exogenous EGF tested and by the neutralizing EGF receptor antibody Mab 425. These results suggest that the high level of tyrosine phosphorylated EGF receptor present in these cells is the direct result of receptor overexpression and not the result of the presence of a stimulatory ligand. Thus, SUM-16LN represents a human breast cancer cell strain that exhibited genetic and cellular characteristics of advanced human breast cancer cells. Nevertheless, these cells exhibited a finite proliferative lifespan in culture, suggesting that cellular immortalization is not a phenotype expressed by all human breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8018955     DOI: 10.1007/bf00666588

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  24 in total

1.  Immortalization in culture: occurrence at a late stage in the progression of breast cancer.

Authors:  H S Smith; S R Wolman; S H Dairkee; M C Hancock; M Lippman; A Leff; A J Hackett
Journal:  J Natl Cancer Inst       Date:  1987-04       Impact factor: 13.506

2.  Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells.

Authors:  G N Gill; C S Lazar
Journal:  Nature       Date:  1981-09-24       Impact factor: 49.962

3.  Clonal proliferation of cultured nonmalignant and malignant human breast epithelia.

Authors:  H S Smith; S Lan; R Ceriani; A J Hackett; M R Stampfer
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

4.  The influence of growth factors on the proliferative potential of normal and primary breast cancer-derived human breast epithelial cells.

Authors:  S P Ethier; R M Summerfelt; K C Cundiff; B B Asch
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

5.  Differential tumorigenicity of two autologous human breast carcinoma cell lines, HMT-3909S1 and HMT-3909S8, established in serum-free medium.

Authors:  O W Petersen; B van Deurs; K V Nielsen; M W Madsen; I Laursen; I Balslev; P Briand
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

6.  Preservation of defined phenotypic traits in short-term cultured human breast carcinoma derived epithelial cells.

Authors:  O W Petersen; B van Deurs
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

7.  Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media.

Authors:  S P Ethier; M L Mahacek; W J Gullick; T S Frank; B L Weber
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

8.  Influence of hormone and growth factor interactions on the proliferative potential of normal rat mammary epithelial cells in vitro.

Authors:  S P Ethier; A Kudla; K C Cundiff
Journal:  J Cell Physiol       Date:  1987-07       Impact factor: 6.384

Review 9.  Allosteric regulation of the epidermal growth factor receptor kinase.

Authors:  J Schlessinger
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

10.  Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification.

Authors:  P Meltzer; A Leibovitz; W Dalton; H Villar; T Kute; J Davis; R Nagle; J Trent
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

View more
  4 in total

1.  Establishment and characterization of a cell line (NABCA) derived from metastatic lymph nodes of breast scirrhous carcinoma.

Authors:  Satoshi Ohi; Shigeya Kyoda; Isao Tabei; Kouzou Ninomiya; Kayoko Sugiyama; Hisashi Hashimoto; Toshiaki Tachibana; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2006-11       Impact factor: 4.174

Review 2.  Human breast cancer cell lines as models of growth regulation and disease progression.

Authors:  S P Ethier
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-01       Impact factor: 2.673

3.  Molecular cytogenetic analysis of 11 new breast cancer cell lines.

Authors:  F Forozan; R Veldman; C A Ammerman; N Z Parsa; A Kallioniemi; O P Kallioniemi; S P Ethier
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

4.  Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysis.

Authors:  Santhi Latha Pandrangi; Sarangadhara Appala Raju Bagadi; Navin Kumar Sinha; Manoj Kumar; Rima Dada; Meena Lakhanpal; Abha Soni; Shreshtha Malvia; Sheeba Simon; Chintamani Chintamani; Ravindar Singh Mohil; Dinesh Bhatnagar; Sunita Saxena
Journal:  Cancer Cell Int       Date:  2014-02-05       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.